Quality of life after VATS lung resection and SABR for early-stage non-small cell lung cancer: a longitudinal study

Lung cancer is the third most common cancer in the UK, accounting for almost 13% of all new cancer cases (2017)[1]. When Non-Small Cell Lung Cancer (NSCLC) is diagnosed at an early-stage (Stage I-II), surgical resection is the main guideline-recommended curative treatment, with five-year survival rates from 90% for Stage IA to 65% for Stage IIA[2]. Open lung resection has been increasingly replaced by a minimal access video-assisted thoracoscopic surgery (VATS) resulting in reduced complications and faster recovery[3].

Source: Lung Cancer - October 23, 2021 Category: Cancer & Oncology Authors: Cecilia Pompili, Zoe Rogers, Kate Absolom, Patricia Holch, Beverly Clayton, Matthew Callister, Johnathan Robson, Alessandro Brunelli, Kevin Franks, Galina Velikova Source Type: research